{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:39:41Z","timestamp":1790739581324,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite advancements in the treatment of non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>odgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>), patients continue to relapse and thus a need for new targeted therapies remains. The <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>40 receptor is highly expressed on neoplastic <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> cells and activation leads to enhanced proliferation and survival. Lucatumumab (<jats:styled-content style=\"fixed-case\">HCD<\/jats:styled-content>122) is a fully human antagonistic <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>40 monoclonal antibody. A phase <jats:styled-content style=\"fixed-case\">IA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study was designed to determine the maximum tolerated dose (<jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content>) and activity of lucatumumab in patients with relapsed\/refractory lymphoma. Determination of the <jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content> was the primary objective of the phase <jats:styled-content style=\"fixed-case\">IA<\/jats:styled-content> dose escalation portion and clinical response was the primary objective of the phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> dose expansion portion. Patients received escalating doses of lucatumumab administered intravenously once weekly for 4\u00a0weeks of an 8\u2010week cycle. <jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content> was determined at 4\u00a0mg\/kg of lucatumumab. A total of 111 patients with <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a074) and <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a037) were enrolled. Responses were observed across various lymphoma subtypes. The overall response rate by computed tomography among patients with follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>) and marginal zone lymphoma of mucosa\u2010associated lymphatic tissue (<jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">MALT<\/jats:styled-content>) was 33\u00b73% and 42\u00b79%, respectively. Lucatumumab demonstrates modest activity in relapsed\/refractory patients with advanced lymphoma, suggesting that targeting of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>40 warrants further investigation.<\/jats:p>","DOI":"10.1111\/bjh.12630","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T07:45:55Z","timestamp":1384328755000},"page":"258-265","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Phase <scp>IA<\/scp>\/<scp>II<\/scp>, multicentre, open\u2010label study of the <scp>CD<\/scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non\u2010<scp>H<\/scp>odgkin or <scp>H<\/scp>odgkin lymphoma"],"prefix":"10.1111","volume":"164","author":[{"given":"Michelle","family":"Fanale","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Jewish General Hospital McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal\u2010C\u00e9ligny","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l'Ouest Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae S.","family":"Heo","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Seoul National University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital of Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"IRCCS National Cancer Institute University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Center for Lymphoma Massachusetts General Hospital Cancer Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Department of Haematology Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies and Molecular Medicine University of Leicester Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carreon","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Ewald","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Baeck","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3017"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.605190"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09251.x"},{"key":"e_1_2_7_7_1","first-page":"343","article-title":"CD40\u2010CD154 interaction in experimental and human disease (review)","volume":"3","author":"Biancone L.","year":"1999","journal-title":"International Journal of Molecular Medicine"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001620"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.681655"},{"key":"e_1_2_7_10_1","first-page":"780","article-title":"CD40 antigen expression on Reed\u2010Sternberg cells. A reliable diagnostic tool for Hodgkin's disease","volume":"146","author":"Carbone A.","year":"1995","journal-title":"The American Journal of Pathology"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.780.bloodjournal853780"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_13_1","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B\u2010cell non\u2010Hodgkin's lymphoma","volume":"35","author":"Dotan E.","year":"2010","journal-title":"P & T: A Peer\u2010Reviewed Journal for Formulary Management"},{"issue":"4","key":"e_1_2_7_14_1","first-page":"145","article-title":"A phase 2B trial comparing dacetuzumab + R\u2010ICE vs placebo + R\u2010ICE in patients with relapsed diffuse large B\u2010cell lymphoma","volume":"22","author":"Fayad L.","year":"2011","journal-title":"Annals of Oncology"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.710328"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286159502900324"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.12.3378.bloodjournal85123378"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.67.1.2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0479"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084756"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131813"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/31002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026451721686"},{"key":"e_1_2_7_25_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1399"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2449.2449"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3311"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12630","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:09:40Z","timestamp":1696306180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/bjh.12630"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12630","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]},"assertion":[{"value":"2013-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}